5 active not recruiting, 4 recruiting, 2 completed, 2 terminated. 9 Phase 2, 5 Phase 1, 2 Phase 3.
Follow Stage IV Intrahepatic Cholangiocarcinoma AJCC v8: new trials by email Literature Review of Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 trials Research Report on Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma Angiography, Biopsy, Biospecimen Collection - Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma | Phase 1 | Recruiting | Mayo Clinic | 16 | 2024-06-06 | 2026-05-13 |
| NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma Biospecimen Collection, Computed Tomography, Heat Shock Factor 1 Pathway Inhibitor NXP800 - Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma | Phase 1 | Terminated | Mayo Clinic | 7 | 2024-05-31 | 2025-12-22 |
| Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) Binimetinib, Biopsy Procedure, Biospecimen Collection - Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 17 | 2024-02-09 | 2026-10-19 |
| Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma | Phase 2 | Active not recruiting | University of Kansas Medical Center | 15 | 2024-02-01 | 2026-02-24 |
| Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases Cisplatin, Gemcitabine, Nab-paclitaxel - Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 12 | 2022-09-19 | 2026-08-03 |
| Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer Atezolizumab, Biopsy, Biospecimen Collection - Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 57 | 2021-12-15 | 2025-05-23 |
| Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma Bintrafusp Alfa, Biopsy, Hypofractionated Radiation Therapy - Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 2 | 2021-08-31 | 2026-09-14 |
| mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma Dexamethasone, Floxuridine, Implanted Medical Device - Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Phase 2 | Terminated | OHSU Knight Cancer Institute | 5 | 2021-04-28 | 2026-06-25 |
| Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver Carboplatin, Paclitaxel, Pevonedistat - Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2020-03-16 | 2026-10-22 |
| Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer Atezolizumab, Bevacizumab, External Beam Radiation Therapy - Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 85 | 2019-09-19 | 2026-10-05 |
| Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Cisplatin, Gemcitabine Hydrochloride, Nab-paclitaxel - Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8 | Phase 3 | Completed | SWOG Cancer Research Network | 452 | 2019-02-07 | 2026-01-12 |
| Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer Atezolizumab, Biopsy, Biospecimen Collection - Gallbladder Carcinoma, Metastatic Cholangiocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 86 | 2018-02-08 | 2024-04-05 |
Cholangiocarcinoma (14) · Gallbladder Neoplasms (6) · Carcinoma, Hepatocellular (3) · Klatskin Tumor (3)
Adenocarcinoma (14) · Carcinoma (14) · Neoplasms (14) · Neoplasms by Histologic Type (14) · Neoplasms, Glandular and Epithelial (14) · Digestive System Diseases (9) · Digestive System Neoplasms (9) · Neoplasms by Site (9) · Biliary Tract Diseases (6) · Biliary Tract Neoplasms (6) · Gallbladder Diseases (6) · Liver Diseases (3) · Liver Neoplasms (3)
Magnetic Resonance Spectroscopy (9) · Specimen Handling (9) · Biopsy (7) · Disulfides (5) · Immunoglobulin G (5) · 1,2-diaminocyclohexaneplatinum II citrate (4) · Cisplatin (4) · Gemcitabine (4) · Platinum (4) · durvalumab (4) · Taxes (3) · atezolizumab (3) · 130-nm albumin-bound paclitaxel (2) · Albumin-Bound Paclitaxel (2) · Leucovorin (2)
National Cancer Institute (NCI) (4) · Mayo Clinic (3) · City of Hope Medical Center (1) · ECOG-ACRIN Cancer Research Group (1) · M.D. Anderson Cancer Center (1) · OHSU Knight Cancer Institute (1) · Ohio State University Comprehensive Cancer Center (1) · SWOG Cancer Research Network (1) · University of Kansas Medical Center (1)
United States (13)
Nilofer S Azad (2) · Ardaman Shergill (1) · Daneng Li, MD (1) · Deirdre J Cohen (1) · Dustin A Deming (1) · Eugene J Koay (1) · Lewis R. Roberts, MD, PhD (1) · Lionel Kankeu Fonkoua, MD (1) · Mitesh J. Borad, MD (1) · Mustafa Raoof, MD (1) · Rachna Shroff (1) · Sameek Roychowdhury, MD, PhD (1) · Skye C Mayo, MD, MPH (1) · Umair Majeed, MD (1)
PMID 34907910, PMID 39263892, PMID 39671534, PMID 39932259, PMID 40717483, PMID 40812353
U10CA180820 (2), UM1CA186691 (2), P30CA033572 (1), P30CA168524 (1), R01CA274985 (1), R01CA294704 (1), U10CA180821 (1), U10CA180888 (1)